Panax-derived ginsenosides in diabetes-associated cognitive dysfunction: mechanistic evidence and translational...

Diabetes-associated cognitive dysfunction (DACD) arises from interacting metabolic, vascular, inflammatory, and neuronal insults, but evidence for Panax-derived interventions is often overgeneralized across chemically non-equivalent materials. This critical narrative review evaluated whether defined Panax-derived saponins support a coherent mechanism of DACD and identified the evidence needed for translation. A structured multilingual search of eight bibliographic databases, supplemented by a targeted search of Cochrane CENTRAL, followed by deduplication and full-text reassessment, yielded 59 records: 16 A1 in vivo studies relevant to DACD (direct or near-direct), six neural-cell studies, 17 auxiliary Panax/barrier/formulation studies, and 20 contextual records. Purified monomers, the active metabolite compound K, saponin fractions, extracts, formulations, and combination interventions were appraised as non-interchangeable exposures. The most consistent signal was improved learning or memory accompanied by hippocampal or cortical tissue protection. Mechanistic findings converged on three connected but partly parallel processes: impaired brain insulin signaling and neuronal glucose handling; advanced glycation end product/methylglyoxal-associated oxidative and organelle stress; and glial-inflammasome amplification. Causal support was uneven, and brain exposure or central target engagement was rarely demonstrated. Most animal studies used young or adult animals of one sex and preventive or early-treatment designs, while several risk-of-bias domains were insufficiently reported. Panax-derived saponins should therefore be regarded as preclinical modulators of hippocampal metabolic-inflammatory-neuronal injury, not established DACD treatments. Translation requires defined interventions, parent/metabolite profiling, quantitative brain exposure, target-engagement assays, delayed-treatment and reversal designs, and clinically aligned biomarkers.